ThriftyCents, I don't think the Mild-to-Moderat
Post# of 148179
I don't think the Mild-to-Moderate has an interim analysis. There might be stoppage due to safety (we all know this will not happen) and/or futility or large difference between groups (Leronlimab is vastly superior).
However, this is a small number of patients (75) and the trial is of short duration (14 days for each patient).
So, I believe we will need to wait a couple of weeks or so to get the results (FDA will be doing this quick under the circumstances, I would think).
imho.